A Phase 1 interventional study of BIBF 1120 in Tumors, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 50 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BIBF 1120
Maximum Tolerated Dose (MTD) of BIBF 1120
Time frame: Up to 7 months
Incidence and intensity of Adverse Events according to common toxicity criteria (CTC) associated with increasing doses of BIBF 1120
Time frame: Up to 7 months
Transfer constant (Ktrans)
Time frame: Screening, day 2, 28 and 56
Extravascular-extracellular leakage volume (ve)
Time frame: Screening, day 2, 28 and 56
Area under the gadolinium concentration time curve [0-60 seconds] (AUC[Gd])
Time frame: Screening, day 2, 28 and 56
Relative blood volume (rBV)
Time frame: Screening, day 2, 28 and 56
Mean transit time (MTT)
Time frame: Screening, day 2, 28 and 56
Relative blood flow (rBF)
Time frame: Screening, day 2, 28 and 56
Volume of tumour showing contrast uptake
Time frame: Screening, day 2, 28 and 56
Volume of tumour showing no contrast uptake
Time frame: Screening, day 2, 28 and 56
Restricted diffusion
Time frame: Screening, day 2, 28 and 56
Vessel size index
Time frame: Screening, day 2, 28 and 56
Change in Eastern Cooperative Oncology Group (ECOG) performance score
Time frame: Baseline, up to 7 months
Objective tumour responses according to the response evaluation criteria in solid tumour (RECIST)
Time frame: Baseline, up to 7 months
Area under the plasma concentration-time curve following the first dose of uniform intervals τ over the time interval from zero to 24 hours (AUCτ,1)
Time frame: up to 24 hours after the first dose on day 1
Area under the plasma concentration-time curve over the time interval from zero to the time of the last quantifiable drug concentration (AUC0-tz)
Time frame: up to 24 hours after the first dose on day 1
Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-∞)
Time frame: up to 24 hours after the first dose on day 1
Maximum measured plasma concentration following the first dose of uniform intervals τ (Cmax,1)
Time frame: up to 24 hours after the first dose on day 1
Time from dosing to the maximum plasma concentration following the first dose of uniform intervals τ (tmax,1)
Time frame: up to 24 hours after the first dose on day 1
Terminal half-life (t1/2)
Time frame: up to 24 hours after the first dose on day 1
Mean residence time (MRTpo)
Time frame: up to 24 hours after the first dose on day 1
Apparent clearance (CL/F)
Time frame: up to 24 hours after the first dose on day 1
Apparent volume of distribution during the terminal phase (Vz/F)
Time frame: up to 24 hours after the first dose on day 1
Area under the plasma concentration-time curve over the dosing interval τ (24 h) at steady state (AUCτ,ss)
Time frame: up to 24 hours after drug administration on day 27
Predose plasma concentration at steady state immediately before dosing (Cpre,ss)
Time frame: up to 24 hours after drug administration on day 27
Maximum plasma concentration at steady state over the dosing interval τ (Cmax,ss)
Time frame: up to 24 hours after drug administration on day 27
Time from dosing to the maximum plasma concentration at steady state over the dosing interval τ (tmax,ss)
Time frame: up to 24 hours after drug administration on day 27
Terminal half-life at steady state (t1/2,ss)
Time frame: up to 24 hours after drug administration on day 27
Apparent clearance at steady state (CL/F,ss)
Time frame: up to 24 hours after drug administration on day 27
Mean residence time at steady state (MRTpo,ss),
Time frame: up to 24 hours after drug administration on day 27
Apparent volume of distribution during the terminal phase at steady state (Vz/F,ss)
Time frame: up to 24 hours after drug administration on day 27
Accumulation ratio (RA)
Time frame: up to 24 hours after drug administration on day 27
Minimum measured plasma concentration following the first dose of uniform intervals τ (Cmin,1)
Time frame: up to 24 hours after the first dose on day 1
Time from first dosing to the minimum plasma concentration over the dosing interval τ (tmin,1)
Time frame: up to 24 hours after the first dose on day 1
Minimum measured plasma concentration at steady state over the dosing interval τ (Cmin,ss)
Time frame: up to 24 hours after drug administration on day 27
Time from last dosing to the minimum plasma concentration at steady state over the dosing interval τ (tmin,ss)
Time frame: up to 24 hours after drug administration on day 27
Predose concentration of the 15th dose over the dosing interval τ (Cpre,15)
Time frame: pre-dose on day 15
No study locations are listed for this record.
The record gives a start of Jun 2003 and a primary completion of Jun 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib